Genetic and nongenetic mechanisms of menin inhibitor resistance in acute leukemia

Abstract Menin inhibitors have emerged as effective targeted therapies for acute leukemias with KMT2A rearrangements and NPM1 mutations. By disrupting the menin-KMT2A interaction, these agents suppress canonical menin-dependent leukemogenic transcriptional programs. However, primary resistance and relapse remain major clinical challenges. Acquired MEN1 mutations cause on-target resistance by impairing inhibitor binding while preserving menin-KMT2A function. Increasing clinical and experimental evidence indicates that suppression of canonical menin targets does not invariably result in leukemia control. Non- MEN1 resistance can involve failure to establish stable transcriptional repression, persistence of noncanonical menin-regulated transcription, impaired growth-arrest or apoptotic responses, and broader epigenomic or lineage-state adaptation. These findings support a multistep model in which target engagement, canonical transcriptional suppression, stable repression, and downstream cell-fate responses make distinct contributions to leukemia control. We review these emerging mechanisms and highlight the need to define their prevalence and clinical relevance through longitudinal studies of patients before treatment, during response, and at resistance.

Authors

Publication Details

Journal
International Journal of Hematology
Published
2026-11-14
DOI
https://doi.org/10.1007/s12185-026-04315-x
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genetic and nongenetic mechanisms of menin inhibitor resistance in acute leukemia

Rui Lu, Xinyue Zhou
International Journal of Hematology
Acute Myeloid Leukemia Research
article

Genetic and nongenetic mechanisms of menin inhibitor resistance in acute leukemia

Rui Lu, Xinyue Zhou
article en

Abstract

Abstract Menin inhibitors have emerged as effective targeted therapies for acute leukemias with KMT2A rearrangements and NPM1 mutations. By disrupting the menin-KMT2A interaction, these agents suppress canonical menin-dependent leukemogenic transcriptional programs. However, primary resistance and relapse remain major clinical challenges. Acquired MEN1 mutations cause on-target resistance by impairing inhibitor binding while preserving menin-KMT2A function. Increasing clinical and experimental evidence indicates that suppression of canonical menin targets does not invariably result in leukemia control. Non- MEN1 resistance can involve failure to establish stable transcriptional repression, persistence of noncanonical menin-regulated transcription, impaired growth-arrest or apoptotic responses, and broader epigenomic or lineage-state adaptation. These findings support a multistep model in which target engagement, canonical transcriptional suppression, stable repression, and downstream cell-fate responses make distinct contributions to leukemia control. We review these emerging mechanisms and highlight the need to define their prevalence and clinical relevance through longitudinal studies of patients before treatment, during response, and at resistance.

International Journal of Hematology
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon